Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Argenica Therapeutics Ltd (AU:AGN)
ASX:AGN
RESEARCH TOOLSreports
Argenica Therapeutics Ltd (AGN) Share Price & Analysis
3 Followers
AGN Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.30 - AU$0.75
Previous CloseAU$0.55
Volume22.02K
Average Volume (3M)141.60K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)AU$8.91M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)-10.6
Beta0.76
Next Earnings
Aug 21, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume141,604
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside80.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Argenica Therapeutics Ltd News
PremiumCompany Announcements
Argenica Begins Key Stroke Treatment Trials
PremiumCompany Announcements
Arigenica Therapeutics Expands ASX Quotation
PremiumCompany Announcements
Argenica Therapeutics Plans New Securities Issue
PremiumCompany Announcements
Argenica Therapeutics Plans New Options Issue
PremiumCompany Announcements
Argenica Therapeutics Plans New Options Issue
PremiumCompany Announcements
Argenica Therapeutics Awaits Capital Raising RevealOptions Prices
Currently, No data available
---
Ownership Overview
4.05%
Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
95.95% Public Companies and
Individual Investors
AGN FAQ
What was Argenica Therapeutics Ltd’s price range in the past 12 months?
Argenica Therapeutics Ltd lowest share price was AU$0.29 and its highest was AU$0.75 in the past 12 months.
What is Argenica Therapeutics Ltd’s market cap?
Currently, no data Available
When is Argenica Therapeutics Ltd’s upcoming earnings report date?
Argenica Therapeutics Ltd’s upcoming earnings report date is Aug 21, 2024 which is in 118 days.
How were Argenica Therapeutics Ltd’s earnings last quarter?
Argenica Therapeutics Ltd released its earnings results on Feb 27, 2024. The company reported -AU$0.014 earnings per share for the quarter, missing the consensus estimate of AU$0.024 by -AU$0.038.
Is Argenica Therapeutics Ltd overvalued?
According to Wall Street analysts Argenica Therapeutics Ltd’s price is currently Undervalued.
Does Argenica Therapeutics Ltd pay dividends?
Argenica Therapeutics Ltd does not currently pay dividends.
What is Argenica Therapeutics Ltd’s EPS estimate?
Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argenica Therapeutics Ltd have?
Argenica Therapeutics Ltd has 122,817,750 shares outstanding.
What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?
Argenica Therapeutics Ltd reported an EPS of -AU$0.014 in its last earnings report, missing expectations of AU$0.024. Following the earnings report the stock price went up 6.897%.
Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?
Currently, no hedge funds are holding shares in AU:AGN
---
Argenica Therapeutics Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (80.18% Upside)
AU$1.00 (80.18% Upside)
Blogger Sentiment
Bullish
AU:AGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.28%
12-Months-Change
Fundamentals
Return on Equity
-69.00%
Trailing 12-Months
Asset Growth
4.16%
Trailing 12-Months
Company Description
Argenica Therapeutics Ltd
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its lead neuroprotective peptide candidate, ARG007 improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.
---
Technical Analysis
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―
Sonic Healthcare Limited
―
Little Green Pharma Ltd.
―
Best Analysts Covering AGN
1 Year
1 Year Success Rate
0/0 ratings generated profit
1 Year Average Return
0.00%
reiterated a buy rating 7 days ago
Copying Unknown Analyst's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
---